(ALXO) ALX Oncology Holdings Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ALXO) ALX Oncology Holdings Inc. Complete Analysis Pack
Unlock Strategic Clarity
This ALX Oncology Holdings Inc. BCG Matrix helps you quickly see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. This page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
0 approved products
ALX Oncology Holdings Inc. has 0 approved products, so it remains a clinical-stage company with no marketed therapy to sell. That means there is no recurring brand demand or proven market share yet. Under BCG logic, ALX Oncology has no true Star today.
Its value still sits in pipeline progress, not product sales, so revenue is not yet driven by an approved asset. Until a therapy wins approval, this segment stays outside the Star box and closer to a high-risk development play.
0 commercial oncology brands
ALX Oncology Holdings Inc. had 0 commercial oncology brands in 2025, so it had no marketed product to build a high-growth, high-share franchise. Revenue was still $0 from product sales, so value stayed tied to clinical development, not market leadership. This makes the Star box a poor fit in 2025.
0 product revenue base
ALX Oncology Holdings Inc. has a 0 product revenue base, so there is no sales engine to fund expansion. In 2025, the business still depended on financing and research execution rather than cash from product sales, which keeps it out of the Star category today.
0 mature market leadership
ALX Oncology Holdings Inc. has no approved product with dominant share in a commercial market, so it does not fit the Stars box. Its lead asset, evorpacept, is still in clinical testing, and the pipeline remains development-stage rather than market-leading. Stars need both fast growth and clear leadership, and ALX Oncology Holdings Inc. has neither today.
No approved-market share
Lead asset still clinical-stage
Growth without leadership is not a Star
R and D first, not profit first
ALX Oncology Holdings Inc. is still spending for trials, not for a profit engine. In 2025, it remained a clinical-stage Company with no meaningful commercial base, so the BCG profile fits a build phase, not a Star.
Capital is going to R&D and pipeline work, which can create a future Star, but end-2025 economics still look development-stage. One line says it all: the portfolio is being built, not harvested.
- 2025 = clinical-stage, not commercial-scale
- Cash goes to trials and pipeline
- No leading revenue position to defend
- Future Star is possible, not current
ALX Oncology Has No BCG Stars in 2025
ALX Oncology Holdings Inc. has no approved products, so it had no true Stars in 2025. Revenue from product sales was $0, and evorpacept stayed clinical-stage, not a market leader. That leaves the BCG Star box empty today.
| Metric | 2025 |
|---|---|
| Approved products | 0 |
| Product revenue | $0 |
| Commercial share | 0% |
| Star fit | No |
What is included in the product
Detailed Word Document
ALX Oncology’s BCG Matrix likely centers on pipeline Question Marks, with no clear Cash Cows and high R&D-driven risk.
Editable Excel File
One-page ALX Oncology BCG Matrix for quick quadrant view and easier strategic decisions
Reference Sources
Provides a traceable source trail for ALX Oncology Holdings Inc., boosting credibility and helping investors verify key assumptions fast.
Cash Cows
0 cash cow products
ALX Oncology Holdings Inc. has 0 Cash Cow products because it has no approved therapy that can generate steady cash flow. With no mature, high-share asset, the portfolio does not show the low-growth, high-margin profile of a Cash Cow. In its latest filings, the Company still relied on clinical-stage development, not product sales.
0 recurring product sales
ALX Oncology Holdings Inc. has 0 recurring product sales, so it has no steady oncology gross margin pool to fund other programs. Cash generation is still external, not operational, with the company remaining a pre-commercial, development-stage business. In 2025, that means cash burn depends on financing and pipeline progress, not on repeat product revenue.
0 royalty scale
ALX Oncology Holdings Inc. has no meaningful royalty base yet, so this is not a Cash Cow. Partner cash flows still depend on development milestones and trial execution, not recurring product sales or royalties. In the latest public filings, that leaves royalty scale at 0, with no stable, high-margin revenue stream to support the BCG Cash Cow label.
0 dividend funding asset
ALX Oncology Holdings Inc. has no cash cow: it generated no product revenue in its latest filings and ended 2024 with about $140 million in cash and investments, which is being used for clinical trials and overhead, not dividends. With a net loss still in the tens of millions, the business is funding survival, so BCG Cash Cow status is absent.
- No dividend funding asset
- Cash goes to R&D and operations
- No mature unit to return capital
This means ALX Oncology depends on capital markets, not internal cash flow, to fund the pipeline.
Cash is consumed by trials
ALX Oncology Holdings Inc. is still in investment mode, not harvest mode. In 2025, it continued to burn cash on R and D, manufacturing, and clinical trials, with no product revenue to offset those costs and a net loss still in the tens of millions each quarter.
- Cash funds trials, not dividends
- No mature operating cash engine
- Spending stays tied to pipeline
The pattern fits a Cash Cow only by contrast: the portfolio is consuming cash, not generating it.
ALX Oncology Has No Cash Cow Yet
ALX Oncology Holdings Inc. has no Cash Cow because it still reported 0 product revenue in its latest filing and remains pre-commercial. Cash and investments were about $140 million at year-end 2024, but that cash is funding R&D and trials, not steady operating profit. So there is no mature, high-share asset to harvest.
| Metric | Latest data |
|---|---|
| Product revenue | 0 |
| Cash and investments | ~$140 million |
| Cash Cow count | 0 |
Get Your Copy
ALX Oncology Holdings Inc. Reference Sources
You're previewing the exact ALX Oncology Holdings Inc. BCG Matrix document you'll receive after purchase. What you see here is the final, fully formatted file—no sample pages, no hidden content. Once purchased, the same report is delivered instantly for your use.
Dogs
0 obsolete commercial assets
ALX Oncology has 0 obsolete commercial assets because it has no legacy marketed drug losing share in a mature market; its portfolio is still development-stage. In FY2025, the Company reported no product revenue, so there is no fading commercial franchise to place in the Dogs bucket. The risk is clinical, not commercial: value depends on trial progress for evorpacept and other pipeline assets.
0 low-share mature brand
ALX Oncology Holdings Inc. shows no approved brand, so there is no low-share, low-growth product to divest. Its pipeline is still earlier than the point where a classic BCG Dog usually forms, with evorpacept still the main asset in clinical development. That keeps the Dog bucket at 0, not 1.
Preclinical ALTA-002
ALTA-002 is still preclinical, so it has 0 market share and 0 sales. That makes it a pure option on future data, not a current business driver for ALX Oncology Holdings Inc. If it fails to show clear clinical differentiation, it could turn into a capital trap; for now, it fits the Dogs box only as a speculative asset.
Selexis and Crystal Bioscience licenses
Selexis and Crystal Bioscience licenses are enabling agreements, not revenue brands, so they sit in the Dogs bucket unless they directly lift a lead asset into approval. ALX Oncology reported $46.6 million in cash, cash equivalents, and short-term investments at March 31, 2025, with a $29.5 million net loss in Q1 2025, so capital is still being pulled toward core pipeline work. Their value is mainly technical support, not standalone sales.
- Support development, not product revenue
- Depend on lead-program success
- Weak BCG stand-alone economics
Tallac collaboration economics
Tallac collaboration economics give ALX Oncology Holdings Inc. extra science options, but not a proven cash engine. If a partnered program never reaches approval or launch, shared upside can shrink and the return profile weakens. In BCG terms, this is support capital, not a durable "Star" or "Cash Cow".
- Optionality rises; cash flow does not.
- Shared economics cap future upside.
- Best viewed as a supporting deal.
ALX Oncology Has No Dogs in 2025—Just Pipeline Risk and Cash Burn
ALX Oncology Holdings Inc. has no true Dogs in FY2025 because it had no approved products, no product revenue, and no mature low-share brand to harvest or exit. The only near-term drag is capital burn: Q1 2025 net loss was $29.5 million, with $46.6 million in cash, cash equivalents, and short-term investments at March 31, 2025. So the Dog bucket stays at 0; the risk is pipeline failure, not legacy decline.
| Metric | FY2025 / Q1 2025 |
|---|---|
| Product revenue | $0 |
| Net loss | $29.5M |
| Cash and investments | $46.6M |
Question Marks
Evorpacept ALX148 phase 1b/2
Evorpacept, ALX148, is ALX Oncology Holdings Inc.'s lead CD47 blocker and sits in multiple phase 1b/2 studies, including ARC-9 in HER2-positive gastric cancer. Its market case is still unproven, so it stays a Question Mark in the BCG Matrix. If response and safety data keep tracking well, it is the clearest path to future Star status.
Merck head and neck phase 2
ALX148’s Merck-sponsored phase 2 with pembrolizumab in head and neck squamous cell carcinoma targets a large, active market with about 900,000 new head and neck cancer cases and 450,000 deaths worldwide in 2022. If the readout is positive, it could lift ALX148 from a Question Mark toward a stronger commercial position. The upside is real, but clinical risk still dominates.
Zymeworks HER2 phase 1
ALX148 plus zanidatamab is still in phase 1, so ALX Oncology Holdings Inc. has no share yet, but the path is broad: zanidatamab is being tested in HER2-expressing breast cancer and other solid tumors. HER2-positive disease is about 20% of breast cancers, and the commercial prize is large, but this stays a Question Mark until data prove better outcomes.
Blood cancer expansion
Blood cancer expansion is a real Question Mark for ALX Oncology Holdings Inc.: myelodysplastic syndromes, acute myeloid leukemia, and non-Hodgkin’s lymphoma are large, high-need markets, with U.S. annual incidence around 10,000, 20,000, and 80,000 cases, respectively. But the program is still precommercial, so there is no sales proof yet and clinical risk remains high.
- Large unmet need
- Precommercial, unproven asset
- High upside, high risk
ALTA-002 preclinical TRAAC
ALTA-002 is a preclinical SIRPα TRAAC that aims to boost both innate and adaptive immunity, but it has no human data yet. In BCG terms, that makes it a classic Question Mark: the idea fits a fast-growing immuno-oncology market, but clinical proof is still missing. The upside is real, but so is the risk.
- Preclinical only; no patient data.
- SIRPα target; immune activation focus.
- High growth, high uncertainty profile.
ALX Oncology’s Early-Stage Pipeline: High Risk, High Upfront Potential
ALX Oncology Holdings Inc.’s Question Marks are still early, high-risk assets: evorpacept is in phase 1b/2 and phase 2, ALX148 plus zanidatamab is in phase 1, and ALTA-002 is preclinical. The upside is tied to large cancer markets, but none has proven commercial sales yet.
| Asset | Status | Signal |
|---|---|---|
| Evorpacept | Phase 1b/2 and 2 | No sales proof |
| ALX148 plus zanidatamab | Phase 1 | Early data only |
| ALTA-002 | Preclinical | No human data |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.